Lilly pipeline chokes again as patent expiries loom
July 11 2012
Lilly's latest R&D disappointment, a schizophrenia drug dubbed mGlu2/3, wasn't a stock killer, but it's yet another in a string ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.